HLVX HilleVax
- 13.610
- -0.410-2.92%
HilleVax News
HilleVax(HLVX.US) Director Sells US$96,770.49 in Common Stock
$HilleVax(HLVX.US)$ Director Kohli Aditya sold 6,898 shares of common stock on May 1, 2, 3, 2024 at an average price of $14.0288 for a total value of $96,770.49.Source: Announcement What is statement
HilleVax Insiders Sell US$1.1m Of Stock, Possibly Signalling Caution
HilleVax, Inc. (NASDAQ:HLVX) shareholders might have a reason to worry after multiple insiders sold their shares over the last year. Knowing whether insiders are buying is usually more helpful when
10 Buy-Rated Stocks With Latest Insider Purchases
HilleVax(HLVX.US) 10% Shareholder Buys US$128.33K in Common Stock
$HilleVax(HLVX.US)$ 10% Shareholder Frazier Life Sciences X, L.P. purchased 8,850 shares of common stock on Apr 4, 2024 at an average price of $14.5 for a total value of $128.33K. This transaction inv
HilleVax(HLVX.US) Director Sells US$264.47K in Common Stock
$HilleVax(HLVX.US)$ Director Kohli Aditya sold 18,000 shares of Common Stock on Apr 3, 4, 5, 2024 at an average price of $14.6926 for a total value of $264.47K.Source: Announcement What is statement o
Hillevax Insider Sold Shares Worth $264,467, According to a Recent SEC Filing
Aditya Kohli, Director, on April 03, 2024, sold 18,000 shares in Hillevax (HLVX) for $264,467. Following the Form 4 filing with the SEC, Kohli has control over a total of 789,776 shares of the company
HilleVax(HLVX.US) Officer Buys US$21,225 in Common Stock
$HilleVax(HLVX.US)$ Officer McLoughlin Sean purchased 1,250 shares of Common Stock on Mar 28, 2024 at an average price of $16.98 for a total value of $21,225.Source: Announcement What is statement of
Kanghua Biotech (300841.SZ) received a down payment of US$15 million from HillEvax
Kanghua Biotech (300841.SZ) announced the signing of a recombinant hexavalent norovirus vaccine with HillEvax...
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI), HilleVax, Inc (HLVX) and Cabaletta Bio (CABA)
Stifel Adjusts HilleVax Price Target to $34 From $30, Maintains Buy Rating
HilleVax (HLVX) has an average rating of Buy and price targets ranging from $21 to $34, according to analysts polled by Capital IQ. Price: 15.72, Change: -0.40, Percent Change: -2.45
HilleVax Insider Sold Shares Worth $985,536,428, According to a Recent SEC Filing
Aditya Kohli, Director, around March 18, 2024, sold 18,000 shares in HilleVax (HLVX) for $985,536,428. Following the Form 4 filing with the SEC, Kohli has control over a total of 807,776 shares of the
HC Wainwright & Co. Reiterates Buy on HilleVax, Maintains $28 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates HilleVax (NASDAQ:HLVX) with a Buy and maintains $28 price target.
HilleVax Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/21/2024 73.81% HC Wainwright & Co. → $28 Reiterates Buy → Buy 12/13/2023 73.81% HC Wainwright & Co. → $
HilleVax, Inc's HIL-214 Vaccine Candidate Promises Broad Protection Against Norovirus, Justifying Buy Rating
HilleVax Q4 Net Loss Widens; Shares Extend Decline After Hours
HilleVax (HLVX) reported a Q4 net loss late Wednesday of $0.78 per diluted share, compared with a loss of $0.56 a year earlier. Analysts polled by Capital IQ expected a loss of $0.83. As expected, no
Recap: HilleVax Q4 Earnings
HilleVax (NASDAQ:HLVX) reported its Q4 earnings results on Wednesday, March 20, 2024 at 04:00 PM.Here's what investors need to know about the announcement.EarningsHilleVax beat estimated earnings by 6
HilleVax Files $500M Mixed Securities Shelf
Express News | HilleVax Q4 2023 GAAP EPS $(0.78) Beats $(0.83) Estimate
HilleVax: Topline Data From NEST-IN1 Phase 2B Clinical Study of HIL-214 in Infants Expected in Mid-2024 >HLVX
HilleVax: Topline Data From NEST-IN1 Phase 2B Clinical Study of HIL-214 in Infants Expected in Mid-2024 >HLVX
HilleVax 4Q Loss $37M >HLVX
HilleVax 4Q Loss $37M >HLVX
Analysis
Price Target
No Data
